Why is the Mesoblast share price in a trading halt?
This morning the biotech company requested a trading halt pending the release of an announcement.
That announcement relates to the United States Food and Drug Administration’s review of its Biologics License Application for RYONCIL (remestemcel-L). Mesoblast is seeking approval for its use in treating paediatric patients with steroid-refractory acute graft versus host disease (SR-aGvHD).
The United States Food and Drug Administration gave its priority review date of 30 September but appears to be either behind schedule or taking its time with the review.
Priority reviews are given to drugs treating serious conditions with the potential to provide significant improvements in safety or effectiveness over existing therapies. They traditionally cut the time in which the administration aims to take action on a drug’s application from ten months to six.
What are the chances of success?
Going into the review, Mesoblast was well-placed to gain approval thanks to its meeting with the Oncologic Drugs Advisory Committee of the Food and Drug Administration in August.
At the meeting, the Committee voted overwhelmingly (9 to 1) in favour that the available data supports the efficacy of remestemcel-L in paediatric patients with SR-aGvHD.
This was a big win the company, as the ODAC plays a key role in whether certain drugs get approval or not. Failure to gain the support of the ODAC would make it almost impossible to then gain FDA approval.
Mesoblast requested that the trading halt continues until it makes its announcement. This is expected to be on Monday 5 October 2020.
This could be an indication that it expects the Food and Drug Administration to make its decision on Friday night (Australian time).
Forget what just happened. We think this stock could be Australia's next MONSTER IPO...
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting...
Because 'Doc' Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Returns as of 6th October 2020
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- Is the Coles (ASX:COL) share price in the buy zone? – October 30, 2020 4:54pm
- Why the Carsales (ASX:CAR) share price dropped 4% today – October 30, 2020 4:19pm
- Why the Medical Developments International (ASX:MVP) share price is tumbling lower – October 30, 2020 3:53pm